Terms: = Prostate cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4 AND Clinical Outcome
5 results:
1. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive prostate cancer: A Systematic Review.
Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
[TBL] [Abstract] [Full Text] [Related]
2. Use of Circulating Tumor DNA for the clinical Management of Metastatic Castration-Resistant prostate cancer: A Multicenter, Real-World Study.
Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
[TBL] [Abstract] [Full Text] [Related]
3. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant prostate cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract] [Full Text] [Related]
4. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant prostate cancer.
Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative prostate cancer.
Bhatia V; Ateeq B
Trends Mol Med; 2019 Nov; 25(11):1024-1038. PubMed ID: 31353123
[TBL] [Abstract] [Full Text] [Related]
